These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 29721378)
1. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Mooradian MJ; Reuben A; Prieto PA; Hazar-Rethinam M; Frederick DT; Nadres B; Piris A; Juneja V; Cooper ZA; Sharpe AH; Corcoran RB; Flaherty KT; Lawrence DP; Wargo JA; Sullivan RJ Oncoimmunology; 2018; 7(5):e1423172. PubMed ID: 29721378 [No Abstract] [Full Text] [Related]
2. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. Clark JI; Singh J; Ernstoff MS; Lao CD; Flaherty LE; Logan TF; Curti B; Agarwala SS; Taback B; Cranmer L; Lutzky J; Luna TL; Aung S; Lawson DH J Immunother Cancer; 2018 Jul; 6(1):76. PubMed ID: 30053905 [TBL] [Abstract][Full Text] [Related]
3. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
6. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Puzanov I; Amaravadi RK; McArthur GA; Flaherty KT; Chapman PB; Sosman JA; Ribas A; Shackleton M; Hwu P; Chmielowski B; Nolop KB; Lin PS; Kim KB Eur J Cancer; 2015 Jul; 51(11):1435-43. PubMed ID: 25980594 [TBL] [Abstract][Full Text] [Related]
9. Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Queirolo P; Spagnolo F; Picasso V; Spano L; Tanda E; Fontana V; Giorello L; Merlo DF; Simeone E; Grimaldi AM; Curvietto M; Del Vecchio M; Bruzzi P; Ascierto PA Oncotarget; 2018 Feb; 9(15):12408-12417. PubMed ID: 29552321 [TBL] [Abstract][Full Text] [Related]
10. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103 [TBL] [Abstract][Full Text] [Related]
11. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705 [TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in non-small-cell lung cancer patients with BRAF Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346 [TBL] [Abstract][Full Text] [Related]
14. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442 [TBL] [Abstract][Full Text] [Related]
15. Improved overall survival in melanoma with combined dabrafenib and trametinib. Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551 [TBL] [Abstract][Full Text] [Related]
16. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523 [TBL] [Abstract][Full Text] [Related]
17. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494 [TBL] [Abstract][Full Text] [Related]
18. Vemurafenib: in unresectable or metastatic melanoma. Keating GM BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753 [TBL] [Abstract][Full Text] [Related]